MUSC is the only US center for Bluebird recruiting and she is the lead investigator. I bet she has been in contact with the Investigator in the French trial.
Look up this trial and see her at the bottom as lead investigator. A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease
That is on clinical trials .gov I hate not being able to provide links in Yahoo!!!! I would post more here if i could.
I found this article this morning. This is the same investigator running the BLUE SCD trial at MUSC!!!!!!!!!
google: MUSC finds 'new areas to target' for sickle cell patients
See the clinical trial called A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease
Rindopepimut Leads to Improved PFS in Compassionate Use Study - See more at: http://www.onclive.com/conference-coverage/sno-2014/Rindopepimut-Leads-to-Improved-PFS-in-Compassionate-Use-Study#sthash.uzWl9inW.dpuf
The reverse split and nasdaq listing is great news. Triillium will be seen as having one of the hottest immunotherapy targets and not look like a canadian penny stock. The float will also be extremely small.
while no data was presented on CELG’s anti-CD47 antibody about to enter the clinic, an interesting abstract from a competitor’s study of anti-CD47 antibodies in murine blood cancer corroborated the potential of anti-CD47 blockade as a promising immune-oncology target, one we believe should get increasing attention within CELG’s early-stage pipeline.
another mention of todays celgene conference call. trial should be starting soon. celgene talking about a pre clinical asset on 2 conference calls in a row is huge imho
(8/15/14) Update on the anti-CD47 cancer therapy clinical trials
The phase-1 clinical trial of the anti-CD47 antibody is designed to test its safety. The trial will accrue one patient per month at very low doses, and the first groups of participants have been identified from among current Stanford Cancer patients. Currently we are not recruiting new patients to this trial.
If enrollments do open up in the future, that information will be posted on this page. When and if enrollments open up, potential inclusion in this phase-1 trial will be based solely on physician referrals. If there are openings for new participants, and if you meet certain requirements, information posted on this page will describe how your physician can submit a request to the clinical trials team to consider your participation.
Given the limited nature of this safety trial, we urge that patients not delay or forgo recommended treatments in hopes of participating in this research effort.
being that we are basically one of the only publicly traded companies that has cd47 in the near term pipeline any sort of efficacy would be a positive and read through to trillium.
“Thirty days from now, the first cancer patient will be treated at Stanford,” Weissman said.
google: McLaughlin Research Institute conference highlights ingenuity